olfactory receptor family 9 subfamily A member 4Genealiases: []
Q-omics provides the consensus-scored OR9A4 profile across patient tissues and cancer cell-line models. OR9A4 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, OR9A4 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, OR9A4 RNA expression shows 7,173 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, LUSC, and THYM as cancer lineages where OR9A4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR9A4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR9A4 survival associations across molecular data types. OR9A4 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR9A4 RNA expression–survival associations across cancer types. High OR9A4 expression shows unfavorable associations in COAD, OV, CHOL and READ, but favorable associations in LAML and THCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for OR9A4 RNA expression.
This table summarizes OR9A4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR9A4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR9A4 shows higher tumor expression in LUSC, HNSC, LUAD, THCA and BRCA. The LUSC box plot shows higher OR9A4 RNA expression in tumor versus normal tissue (log2 FC = +0.166, t-test p < 0.001).
This table shows molecular features associated with OR9A4 in patient tissues and cancer cell lines. In patient samples, OR9A4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, OR9A4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
